Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Optimal Duration of Antiplatelet Therapy After Stent Implantation: Insights from A-CLOSE Trial

1w ago September 5, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

The A-CLOSE trial revealed that while antiplatelet monotherapy reduces bleeding, dual therapy offers better cardiovascular protection for high-risk patients post-stent implantation. These findings were shared at the ESC Congress 2026 and published in the New England Journal of Medicine. This research is significant for Iran as it may influence treatment protocols for cardiovascular patients in the country.

🔍 Quick Context Guide
💡 Bottom Line: The A-CLOSE trial suggests dual antiplatelet therapy is crucial for high-risk patients post-stent, which could reshape treatment approaches in Iran.

👥 Key Players

ESC Congress MENTIONED
Medical conference organizers
"They provide a platform for significant medical research findings that can influence treatment practices globally, including in Iran."
New England Journal of Medicine MENTIONED
Medical journal
"Publishing in this journal indicates high-quality research, impacting clinical guidelines and practices in Iran and beyond."

📰 What Happened

The A-CLOSE trial findings were presented at the ESC Congress 2026, highlighting that while antiplatelet monotherapy reduces bleeding, dual therapy is more effective for preventing cardiovascular events in high-risk patients post-stent implantation.

  • Antiplatelet monotherapy leads to less bleeding.
  • Dual therapy offers better cardiovascular protection for high-risk patients.

💡 Why It Matters

🇮🇷 For Iran: The findings could lead to changes in treatment protocols for cardiovascular patients in Iran, potentially improving patient outcomes.
🌍 Regional: Improved treatment protocols could enhance healthcare standards across the region, influencing neighboring countries.
🌐 International: The results may prompt reevaluation of global antiplatelet therapy guidelines, impacting treatment strategies worldwide.

📚 Background

Antiplatelet therapy is critical for patients with stents to prevent blood clots, and understanding the optimal duration is vital for effective treatment.

Cardiovascular health Stent implantation procedures
📡 Source: NEUTRAL
📊 Confidence: 70%
The information comes from a reputable medical conference and journal, indicating a high level of reliability.

Antiplatelet monotherapy reduced bleeding, but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier. These results, from the A-CLOSE trial, were presented in a Hot Line session at ESC Congress 2026 and were published simultaneously in the New England Journal of Medicine.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →